Authors
Latest:
Dr Agulnik on the Evolving Management of Heterogenous Disease in GISTMark Agulnik, MD, discusses the evolving management of heterogeneous disease types in gastrointestinal stromal tumors.
Latest:
Comprehensive Programs Are Needed to Address Therapeutic Needs in Sickle Cell DiseaseSickle cell disease, a chronic debilitating disorder, is characterized by ongoing hemolytic anemia, vaso-occlusive events, and progressive organ damage.
Latest:
Women in Oncology: Lessons to Tell Up-and-Coming Female OncologistsLaura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.
Latest:
Dr. Cole on Next Steps With Tucatinib in HER2+ Breast CancerJohn Cole, MD, discusses the next steps with tucatinib in HER2-positive breast cancer.
Latest:
Dr Desai on Toxicities Associated with T-DXd in HER2+ Breast CancerNeelam Desai, MD, discusses the toxicity profile of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Latest:
Dr. Cordoba on the Efficacy of Epcoritamab in DLBCLRaul Cordoba, MD, PhD, discusses efficacy data with epcoritamab observed in the phase 1/2 EPCORE NHL-2 trial in relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Dr. Leleu on the Future of Later-Line Therapy in Multiple MyelomaXavier Leleu, MD, PhD, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.
Latest:
Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With AnemiaRebecca Klisovic, MD, discusses 3 case studies about patients with myelofibrosis.
Latest:
Dr. Weksler on Addressing Disparities in Lung Cancer Care DeliveryBenny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.
Latest:
Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer PatientsResults of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.
Latest:
Pembrolizumab/Chemo With or Without Bevacizumab Has Potential as New SOC in Metastatic Cervical CancerNicoletta Colombo, MD, PhD, discusses the practice-changing data to emerge from KEYNOTE-826 and the next steps for the pembrolizumab plus chemotherapy with or without bevacizumab regimen in patients with cervical cancer.
Latest:
Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical CancerMae Zakhour, MD, discusses the utilization of tisotumab vedotin-tftv in cervical cancer.
Latest:
Dr Islam on the Limited Use of Ibrutinib in CLLPrioty Islam, MD, MSc, discusses the current status of the first-generation BTK inhibitor ibrutinib following the FDA approvals of next-generation BTK inhibitors in patients with chronic lymphocytic leukemia and expands on the few instances in the clinic where she may lean toward treatment with ibrutinib instead of the next-generation BTK inhibitors zanubrutinib or acalabrutinib.
Latest:
Dr. Shaukat on the Benefit of Diverse Enrollment in Clinical Trials in CRCAasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.
Latest:
Dr Dahiya on the FDA Approval of Liso-Cel for Relapsed/Refractory Follicular LymphomaSaurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.
Latest:
US Biosimilar Portfolio Hits 10-Year Mark in Growth ModeSince the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.
Latest:
Dr Montes de Oca on the Use of Cryocompression to Reduce Peripheral Neuropathy in Gynecologic CancersMary Katherine Montes de Oca, MD, discusses the use of cryocompression to reduce chemotherapy-induced peripheral neuropathy in gynecologic cancers.
Latest:
Findings Suggest Cholesterol Plays a Surprising Role in Pancreatic CancerAlthough a majority of pancreatic cancer cells are highly dependent on endogenous biosynthesis of cholesterol, new research from investigators at Fox Chase Cancer Center has demonstrated that some more aggressive pancreatic cancers are completely independent of this process.
Latest:
The Future of Molecular Testing in NSCLCThe panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.
Latest:
Dr. Toppmeyer on Sequencing Therapy in HER2+ Breast CancerDeborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.
Latest:
Dr Danilov on the Current and Potential Use of Pirtobrutinib in CLLAlexey Danilov, MD, PhD, discusses the utility of pirtobrutinib in patients with chronic lymphocytic leukemia.
Latest:
Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer ModelsAdrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.
Latest:
Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass MicrospheresRiad Salem, MD, presents slides supporting global real-world data confirming a significant association between tumor-absorbed dose, objective response between tumor-absorbed dose and overall survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 glass microspheres.
Latest:
Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLCMichael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.
Latest:
Dr Lang on Ocular Toxicities Following ADC Treatment in Ovarian CancerSusan Marie Lang, MD, discusses the incidence of ocular toxicity following treatment with mirvetuximab soravtansine in ovarian cancer.
Latest:
Struggling With COVID-19 on the Cancer FloorFor the population of hospitalized patients with cancer, many of whom who have not contracted the disease, COVID-19 has real, immediate consequences; the pandemic has radically altered their end-of-life care.
Latest:
Dr. Silbermann on the CASTOR Trial in Relapsed/Refractory MyelomaRebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.
Latest:
Dr Mattes on the Mechanism of Action of Ipatasertib in HNSCCMalcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.
Latest:
Dr. Majem on the Safety Profile of Osimertinib in EGFR+ NSCLCMargarita Majem, MD, PhD, discusses the safety profile of osimertinib in patients with EGFR-mutated non–small cell lung cancer.
